west china medical publishers
Keyword
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Keyword "视网膜静脉" 159 results
  • A meta-analysis of correlation between antiphospholipid antibodies and retinal vein occlusion

    Objective To evaluate the correlation between antiphospholipid (APLA) antibodies and retinal vein occlusion (RVO). Methods A computerized search was conducted in the Pubmed, Chinese Biological Medicine Database, China National Knowledge Infrastructure, VIP database, Wanfang Database combined with manually searching of literature reference proceedings. The search time was ranged from establishment of each database to August 1st, 2012. After the data extraction, quality of RCT was assessed. The meta analysis was performed by Stata 11.0. Results In total, 12 case-control studies (1324 subjects) that fulfilled the eligibility criteria were included in the meta-analysis involving 505 patients in RVO group and 819 subjects in control group. The odds ratio (OR) and 95% confidence interval (CI) of APLA, anticardiolipin antibodies (ACA), lupus coagulation inhibitor and RVO were 5.01 and 3.33 - 7.53,4.38 and 2.38 - 8.05, 1.72 and 0.73 - .88, 6.02 and 2.06 - 17.63, respectively. The OR and 95% CI of APLA, ACA, lupus coagulation inhibitor and branch RVO were 4.22 and 1.67 - 10.63, 3.69 and 1.32 - 10.32, 2.07 and 0.79 - 5.41, respectively. Conclusions APLA may increase the rick of RVO, especially ACA has a prediction function to RVO. It is necessary to screening for APLA in RVO patients.

    Release date:2016-09-02 05:21 Export PDF Favorites Scan
  • 视网膜中央静脉阻塞并发新生血管性青光眼合并视网膜中央动脉阻塞一例

    Release date:2016-09-02 05:18 Export PDF Favorites Scan
  • Expression of vasoactive molecules in aqueous humor of patients with macular edema secondary to central retinal vein occlusion

    Objective To observe the levels of vascular endothelial growth factor (VEGF), interleukin-6 (IL-6) and monocyte chemotactic protein-1 (MCP-1) in aqueous humor of patients with macular edema secondary to central retinal vein occlusion (CRVO). Methods Forty eyes of 40 consecutive patients with macular edema secondary to CRVO (CRVO group) were enrolled in this study. The patients included 25 males and 15 females. The patient age ranged from 38 to 76 years. The control group was 20 patients with senile cataract who underwent phacoemulsification, including 10 males and 10 females. The levels of VEGF165, VEGF165b, IL-6 and MCP-1 in aqueous humor were determined by enzymelinked immunosorbent assay. The correlation of VEGF, and IL-6, and MCP-1 were analyzed. Results The median aqueous level of VEGF165, IL-6 and MCP-1 were 1089.0, 165.6, 1253.0 pg/ml respectively in CRVO group, which were higher than the control group's results (168.2, 4.7, 216.4 pg/ml respectively), the differences were statistically significant (Z=-4.549, -6.008, -5.343;P<0.001). The VEGF165b in CRVO group and control group were 834.0, 915.9 pg/ml respectively, the difference was not statistically significant (Z=-0.207,P>0.05). The ratio of VEGF165b to VEGF165 in CRVO group and control group were 2.71, 7.28 respectively, the difference was statistically significant (t=-3.007,P<0.05). There was a highly positive correlation between IL-6 and VEGF in CRVO group (r=0.526,P=0.001) and also mild positive correlation in control group (r=0.425,P=0.070). No correlation between MCP-1 and VEGF was observed in both groups (CRVO group: r=0.211,P>0.05. Control group: r=-0.019,P>0.05). Conclusions VEGF165, IL-6 and MCP-1 levels were increased in CRVO patients while the VEGF165b was normal. The ratio between VEGF165b and VEGF165 in aqueous humor of patients with macular edema secondary to CRVO was decreased.

    Release date:2016-09-02 05:22 Export PDF Favorites Scan
  • Serum lipid level of patients with branch retinal vein occlusion

    Objective To observe the serum lipid level of patients with branch retinal vein occlusion (BRVO). Methods A total of 71 BRVO patients (BRVO group) were enrolled in this study. The patients included 31 males and 40 females, with an average age of (52.75plusmn;10.2) years. All the patients were examined for visual acuity, slit lamp ophthalmoscopy combine with preset lens, fundus color photography and fundus fluorescein angiography (FFA) examination. Seventy-two age and sex matched normal subjects were enrolled in this study as control group. The subjects included 32 males and 40 females, with an average age of (53.10plusmn;9.5) years. The BRVO and control group were divided into four subgroup which including age with <40 years, 40-49 years, 50-59 years and ge;60 years. The plasma cholesterol and triglyceride level of BRVO group, control group, and age subgroups of BRVO and control group were comparatively analyzed. Results The average plasma cholesterol levels were (4.529plusmn;0.100) and (4.274plusmn;0.106) mmol/L in BRVO and control group, respectively. There was no difference between two groups (t=-1.738,P>0.05). The average triglyceride levels were (1.500plusmn;0.129) and (1.319plusmn;0.095) mmol/L in BRVO and control group, respectively. There was no difference between two groups (t=-1.135,P>0.05). There was no difference of average plasma cholesterol (t=-1.755, 1.850, -1.892, -0.507) and triglyceride (t=0.846, -0.074, -1.288, -1.887) level in age subgroups of BRVO and control subgroup (P>0.05). Conclusion There is no significant difference of serum lipid level between BRVO patients and controls.

    Release date:2016-09-02 05:22 Export PDF Favorites Scan
  • Clinical analysis of combined central retinal artery and vein occlusion

    Objective To observe the clinical features of combined central retinal artery and vein occlusion. Methods The clinical data of eight patients of combined central retinal artery and vein occlusion diagnosed by fundus examination and fundus fluorescein angiography (FFA) was analyzed retrospectively, including the causes, fundus manifestations and FFA features. Results 4/8 patients had hypertension and dyslipidemia, 2/8 patients had traumatic retrobulbar hemorrhage, one patient had orbital cellulitis and one patient had systemic lupus erythematosus. All the patients had posterior pole retinal edema, hemorrhage, thin retinal artery, dilated vein, and papilledema. FFA showed delayed arterial filling, and there was no filling of retinal arterial branches until the late stage of FFA. Laminar flow delayed in large retinal veins, and there was no filling or only retrograde filling in retinal vein branches. Large areas with dot-like or patchy weak choroidal fluorescence can be observed in five patients. Conclusions Combined central retinal artery and vein occlusion is rare with complex etiology. The fundus manifestations and FFA features are atypical, but have features of central retinal artery occlusion and central retinal vein occlusion.

    Release date:2016-09-02 05:22 Export PDF Favorites Scan
  • Clinical features and outcomes of vitrectomy for diabetic retinopathy with central retinal vein occlusion

    Objective To observe the clinical features and outcomes of vitrectomy for diabetic retinopathy (DR) with central retinal vein occlusion (CRVO) in type 2 diabetes mellitus (T2DM). Methods A total of 192 patients (241 eyes) with proliferative DR (PDR) who underwent vitrectomy were enrolled in this study. All the patients were diagnosed as vitreous hemorrhage (VH) because of suddenly decreased vision. There were 93 eyes with tractional retinal detachment (TRD) and six eyes with neovascularization of iris (NVI). The patients were divided into PDR with CRVO group (group A, 41 eyes) and PDR group (group B, 200 eyes) according to the results of fundus examination. All patients received vitrectomy with silicone oil and C3F8 gas tamponade. There were 138 eyes with silicone oil tamponade which including 30 eyes in group A and 108 eyes in group B. The difference of number in silicone oil-filled eyes in two groups was statistically significant (chi;2=5.110,P<0.05). There were 38 eyes with C3F8 gas tamponade which including six eyes in group A and 32 eyes in group B. There was no difference in C3F8 gas-filled eyes numbers in two groups (chi;2=0.048, P>0.05). The follow-up ranged from one to 60 months, with the mean of (28.69plusmn;17.28) months. The corrected vision, retinal reattachment, persisting macular edema (ME), neovascular glaucoma (NVG) and repeated VH after surgery were comparatively analyzed. Results Of 241 eyes, there were 41 eyes (17.0%) with CRVO. Before surgery, the differences of corrected vision (Z=-0.138), intraocular pressure (t=0.966), whether there was TRD or not (chi;2=0.412), whether underwent panretinal photocoagulation or not (chi;2=1.416) were not statistically significant (P>0.05), but the difference of whether NVI were present or not was statistically significant (chi;2=31.724,P<0.05) between two groups. After surgery, the corrected vision improved in both two groups (Z=2.319, 4.589; P<0.05). There was no difference of corrected vision after surgery between two groups (Z=0.782,P>0.05). Postoperative complications occurred in 94 eyes, including 26 eyes in group A and 68 eyes in group B. The differences of incidence of reoperation (chi;2=0.498), retinal reattachment (chi;2=0.818), persisting ME (chi;2=2.722) between two groups after surgery were not statistically significant (P>0.05). The incidence of repeated VH (chi;2=5.737) and NVG (chi;2=6.604) in group A were higher than those in group B (P<0.05). Conclusions CRVO is commonly found to coexist with DR in T2DM patients with VH. Combined with CRVO patients are more likely to suffer NVI. Vitrectomy can improve the visual function in PDR with CRVO patients.

    Release date:2016-09-02 05:22 Export PDF Favorites Scan
  • 视网膜中央静脉阻塞合并视网膜分支动脉阻塞一例

    Release date:2016-09-02 05:22 Export PDF Favorites Scan
  • 视网膜静脉阻塞抗血管内皮生长因子治疗研究进展

    以血管内皮生长因子(VEGF)为特异性靶点的新疗法,较激光光凝、糖皮质激素等传统治疗方法独具优势,有望成为视网膜静脉阻塞继发黄斑水肿(ME)的一线治疗。其代表药物抗VEGF单克隆抗体ranibizumab、bevacizumab、aflibercept均能非特异性阻断VEGF-A全部亚型,通过抗原-抗体结合反应在局部发挥药理作用。已有的大样本、随机对照临床研究初步肯定其兼具疗效性和安全性,但仍存在ME复发、治疗频繁、个体差异、费用高等诸多问题,且治疗相关并发症及风险尚待进一步观察。为此,有关预后研究、联合治疗等方面研究已有展开。

    Release date:2016-09-02 05:22 Export PDF Favorites Scan
  • 视网膜静脉阻塞继发黄斑水肿的治疗进展

    视网膜静脉阻塞(RVO)继发黄斑水肿(ME)传统的治疗方法主要为激光光凝和以曲安奈德、地塞米松为主的糖皮质激素治疗。近年来,雷珠单抗(商品名Lucentis)、贝伐单抗(商品名Avastin)等抗血管内皮生长因子药物玻璃体腔注射以及玻璃体视网膜手术治疗是RVO继发ME治疗探索的主要方向。虽然许多非随机、缺乏对照的临床试验结果表明这些新的治疗方法能明显改善ME并提高视力,但仍需进行大规模、多中心、随机对照临床试验研究,以更加客观地评价这些疗法的治疗效果和安全性。

    Release date:2016-09-02 05:22 Export PDF Favorites Scan
  • 玻璃体腔注射抗血管内皮生长因子单克隆抗体ranibizumab治疗视网膜静脉阻塞黄斑水肿的研究现状

    玻璃体腔注射抗血管内皮生长因子(VEGF)单克隆抗体ranibizumab(商品名Lucetis) (IVR)治疗视网膜静脉阻塞(RVO)继发黄斑水肿的短期疗效已得到广泛肯定。由于ranibizumab半衰期短,黄斑水肿易复发,需多次注射,增加了患者眼内注射潜在并发症的风险。传统激光光凝治疗是目前治疗RVO黄斑水肿的主要方法,其疗效作用较为持久,相对安全,但对视网膜组织具有一定的破坏作用,对视力改善效果不明显。IVR联合黄斑格栅样激光光凝治疗RVO黄斑水肿相比单纯IVR可减少玻璃体腔反复注射次数,降低眼内注射并发症风险,达到更好的治疗效果,可成为将来治疗的发展趋势。但联合治疗时机的选择以及反复注射存在的潜在危险仍需要大样本的长期前瞻性研究进一步观察验证。

    Release date:2016-09-02 05:22 Export PDF Favorites Scan
16 pages Previous 1 2 3 ... 16 Next

Format

Content